A project to evaluate the results of, and consider additional analyses, use of applicable regulatory programs, and the need for a Phase III trial following completion of an investigator-initiated Phase II trial for ALS, and to formulate a regulatory submission strategy. No statistically significant difference was found, and the future development direction is being reconsidered.